13. Multiple sclerosis/Neuromyelitis optica
3,050 clinical trials,   2,147 drugs   (DrugBank: 348 drugs),   244 drug target genes,   228 drug target pathways
Searched query = "Multiple sclerosis/Neuromyelitis optica", "Multiple sclerosis", "Neuromyelitis optica", "MS", "NMOSD", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03799718 (ClinicalTrials.gov) | March 13, 2019 | 7/1/2019 | Safety and Efficacy of Repeated Administration of NurOwn (MSC-NTF Cells) in Participants With Progressive MS | A Phase 2 Open-label Multicenter Study to Evaluate the Safety and Efficacy of Repeated Administration of NurOwn® [Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors (NTF), MSC-NTF] Cells in Participants With Progressive MS | Multiple Sclerosis, Chronic Progressive | Biological: NurOwn (MSC-NTF cells) | Brainstorm-Cell Therapeutics | NULL | Active, not recruiting | 18 Years | 65 Years | All | 20 | Phase 2 | United States |
2 | NCT03326505 (ClinicalTrials.gov) | September 25, 2017 | 9/5/2017 | Allogenic Mesenchymal Stem Cells And Physical Therapy for MS Treatment | The Effect of Stem Cell Therapy and Comprehensive Physical Therapy in Motor and Non-Motor Symptoms in Patients With Multiple Sclerosis: A Comparative Study. | Multiple Sclerosis | Biological: Umbilical cord derived Mesenchymal Stem Cells;Other: Supervised physical therapy | University of Jordan | NULL | Completed | 18 Years | 65 Years | All | 60 | Phase 1;Phase 2 | Jordan |
3 | NCT02239393 (ClinicalTrials.gov) | June 2015 | 10/9/2014 | Safety and Efficacy of Intravenous Autologous Mesenchymal Stem Cells for MS: a Phase 2 Proof of Concept Study | MEsenchymal Stem Cell Therapy for CAnadian MS Patients | Multiple Sclerosis | Biological: Mesenchymal Stem Cells | Ottawa Hospital Research Institute | NULL | Completed | 18 Years | 50 Years | All | 31 | Phase 2 | Canada |
4 | NCT02495766 (ClinicalTrials.gov) | May 11, 2015 | 3/6/2015 | Autologous Mesenchymal Stromal Cells for Multiple Sclerosis | Treatment of Autologous Mesenchymal Stem Cells Derived From Bone Marrow as a Potential Therapeutic Strategy for the Treatment of Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis;Secondary Progressive Multiple Sclerosis | Drug: XCEL-MC-ALPHA;Drug: Placebo | Banc de Sang i Teixits | Vall d'Hebron Research Institute (VHIR) | Completed | 18 Years | 60 Years | All | 8 | Phase 1;Phase 2 | Spain |
5 | NCT02403947 (ClinicalTrials.gov) | February 2015 | 9/3/2015 | MEsenchymal StEm Cells for Multiple Sclerosis | Treatment of Multiple Sclerosis With Mesenchymal Stem Cells: Phase I/II Study | Multiple Sclerosis | Drug: Mesenchymal stem cells;Drug: Suspension media | University Hospital, Toulouse | NULL | Terminated | 18 Years | 50 Years | All | 1 | Phase 1;Phase 2 | France |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
6 | NCT02418325 (ClinicalTrials.gov) | February 2015 | 8/4/2015 | A Study of Allogeneic Human UC-MSC and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS | An Open-label, Non-randomized, Phase I/II Study of Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and Liberation Therapy (When Associated With Chronic Cerebrovascular Venous Insufficiency) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) | Multiple Sclerosis, Relapsing-Remitting | Biological: Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells;Other: Liberation therapy | Genesis Limited | NULL | Terminated | 18 Years | 60 Years | Both | 69 | Phase 1;Phase 2 | Trinidad and Tobago |
7 | NCT02587715 (ClinicalTrials.gov) | February 2015 | 26/10/2015 | A Study of Allogeneic Human UC-MSC and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS | An Open-label, Non-randomized, Phase I/II Study of Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and Liberation Therapy (When Associated With Chronic Cerebrovascular Venous Insufficiency) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) | Multiple Sclerosis, Relapsing-Remitting | Biological: Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells;Other: Liberation therapy | Novo Cellular Medicine Institute LLP | NULL | Recruiting | 18 Years | 60 Years | Both | 69 | Phase 1;Phase 2 | Trinidad and Tobago |
8 | NCT02166021 (ClinicalTrials.gov) | January 29, 2015 | 20/5/2014 | Clinical Efficacy of Autologous Mesenchymal Bone Marrow Stem Cells in Active & Progressive Multiple Sclerosis | Phase 2 Trial to Investigate the Clinical Efficacy & the Optimal Administration (Based on the Immunological, Clinical & Neuroradiological Effects) of Autologous Mesenchymal Bone Marrow Stem Cells in Active & Progressive Multiple Sclerosis | Multiple Sclerosis (MS) | Biological: Mesenchymal stem cells | Dimitrios Karussis | NULL | Completed | 18 Years | 65 Years | All | 48 | Phase 2 | Israel |
9 | NCT02326935 (ClinicalTrials.gov) | November 2014 | 18/12/2014 | Multi-Center Study Safety of Adipose Derived Mesenchymal Stem Cells for the Treatment of Multiple Sclerosis | Proposal for a Non-randomized, Patient Sponsored, Multi-center Study Studying the Impact and Safety of the Utilization of Culture Expanded Autologous, Adipose-derived Mesenchymal Stem Cells Deployed Via Intravenous Injection for the Treatment of Multiple Sclerosis | Multiple Sclerosis | Biological: Autologous adipose derived mesenchymal cells | American CryoStem Corporation | NULL | Terminated | 18 Years | 65 Years | All | 2 | Phase 1 | Cayman Islands |
10 | EUCTR2012-000734-19-ES (EUCTR) | 10/04/2014 | 10/01/2014 | Bone marrow cell treatment as treatment of multiple sclerosis | Treatment of autologous mesenchymal stem cells derived from bone marrow as a potential therapeutic strategy for the treatment of multiple sclerosis - EMMES | Multiple Sclerosis MedDRA version: 16.1;Level: PT;Classification code 10028245;Term: Multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: XCEL-MC-ALPHA Product Code: XCEL-MC-ALPHA INN or Proposed INN: Autologous adult mesenchymal stem cells from bone marrow expanded and cryopreserved Other descriptive name: Mesenchymal Stem Cells | Banc de Sang i Teixits | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Spain | ||||
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
11 | NCT02034188 (ClinicalTrials.gov) | January 2014 | 9/1/2014 | Feasibility Study of Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells in Patients With Multiple Sclerosis | Feasibility Study of Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells in Patients With Multiple Sclerosis | Multiple Sclerosis | Biological: Umbilical cord mesenchymal stem cells | Translational Biosciences | NULL | Completed | 18 Years | 55 Years | All | 20 | Phase 1;Phase 2 | Panama |
12 | NCT02035514 (ClinicalTrials.gov) | December 2013 | 17/12/2013 | Phase I-II Clinical Trial With Autologous Bone Marrow Derived Mesenchymal Stem Cells for the Therapy of Multiple Sclerosis | Phase I-II Clinical Trial With Autologous Bone Marrow Derived Mesenchymal Stem Cells for the Therapy of Multiple Sclerosis | Relapsing Remitting Multiple Sclerosis (RRMS) | Biological: Bone marrow autologous mesenchymal stem cells transplantation | Germans Trias i Pujol Hospital | Ministerio de Sanidad, Servicios Sociales e Igualdad | Completed | 18 Years | 50 Years | Both | 9 | Phase 1;Phase 2 | Spain |
13 | NCT01730547 (ClinicalTrials.gov) | February 2013 | 9/11/2012 | Mesenchymal Stem Cells for Multiple Sclerosis | Phase 1/2 Clinical Trial With Autologous Mesenchymal Stem Cells for the Therapy of Multiple Sclerosis | Multiple Sclerosis | Biological: Autologous mesenchymal stem cells | Karolinska Institutet | NULL | Recruiting | 18 Years | 50 Years | Both | 15 | Phase 1;Phase 2 | Sweden |
14 | NCT02249676 (ClinicalTrials.gov) | January 2013 | 15/9/2014 | Autologous Mesenchymal Stem Cells for the Treatment of Neuromyelitis Optica Spectrum Disorders | Autologous Mesenchymal Stem Cells for the Treatment of Progressive and Refractory Neuromyelitis Optica Spectrum Disorders: an Open-label Phase 2a Proof-of-concept Study | Devic's Syndrome;Devic's Neuromyelitis Optica;Devic Syndrome;Devic's Disease;Devic Disease | Biological: Autologous mesenchymal stem cells | Tianjin Medical University General Hospital | NULL | Completed | 18 Years | 80 Years | All | 15 | Phase 2 | China |
15 | NCT01606215 (ClinicalTrials.gov) | January 2013 | 21/5/2012 | Stem Cells in Rapidly Evolving Active Multiple Sclerosis | Stem Cells in Rapidly Evolving Active Multiple Sclerosis | Multiple Sclerosis | Drug: Mesenchymal stem cells;Drug: Placebo | Imperial College London | NULL | Completed | 18 Years | 50 Years | All | 21 | Phase 1;Phase 2 | United Kingdom |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
16 | NCT03778333 (ClinicalTrials.gov) | December 1, 2012 | 14/1/2015 | Mesenchymal Stem Cells for Progressive Multiple Sclerosis_Sweden | Mesenchymal Stem Cells for Progressive Multiple Sclerosis_Sweden | Autologous Mesenchymal Stem Cells;Multiple Sclerosis | Biological: Autologous mesenchymal stem cells | Karolinska Institutet | NULL | Completed | 18 Years | 65 Years | All | 7 | Phase 1 | Sweden |
17 | NCT01895439 (ClinicalTrials.gov) | October 2012 | 24/6/2013 | Safety and Efficacy Study of Autologus Bone Marrow Mesenchymal Stem Cells in Multiple Sclerosis | Phase II Study: Use of Autologus Mesenchymal Stem Cells in Multiple Sclerosis Patients Who do Not Respond to Conventional Treatment | Multiple Sclerosis | Biological: Autologous Mesenchymal Stem Cells | University of Jordan | NULL | Completed | 18 Years | 65 Years | All | 13 | Phase 1;Phase 2 | Jordan |
18 | NCT01854957 (ClinicalTrials.gov) | July 2012 | 8/5/2013 | MEsenchymal StEm Cells for Multiple Sclerosis | MEsenchymal StEm Cells for Multiple Sclerosis (MESEMS) Phase I-II Clinical Trial With Autologous Mesenchymal Stem Cells (MSCs) for the Therapy of Multiple Sclerosis | Multiple Sclerosis | Biological: Autologous Mesenchymal Stem Cells | Antonio Uccelli | Azienda Ospedaliera Universitaria Integrata Verona;Ospedale San Raffaele | Recruiting | 18 Years | 50 Years | Both | 20 | Phase 1;Phase 2 | Italy |
19 | EUCTR2012-000518-13-DK (EUCTR) | 21/06/2012 | 21/06/2012 | Own mesenchymal stem cells for multiple sclerosis patients | Immunomodulating and neuroprotective properties of autologous multipotent mesenchymal stem cells in patients with multiple sclerosis - A randomised placebo-controlled double-blinded phase II study - COMSCIMS | Multiple sclerosis MedDRA version: 18.1;Level: PT;Classification code 10028245;Term: Multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Mesenchymal stem/stromal cells Product Name: Mesenchymal stem cells (MSCs) | Prof. Per Soelberg Sørensen | NULL | Not Recruiting | Female: yes Male: yes | Phase 2 | Denmark | |||
20 | NCT01377870 (ClinicalTrials.gov) | December 2011 | 19/6/2011 | Evaluation of Autologous Mesenchymal Stem Cell Transplantation (Effects and Side Effects) in Multiple Sclerosis | Effect and Side Effect of Mesenchymal Stem Cell in Multiple Sclerosis | Multiple Sclerosis | Biological: intravenous injection of mesenchymal stem cells;Biological: injection of cell free media | Royan Institute | NULL | Completed | 18 Years | 55 Years | All | 22 | Phase 1;Phase 2 | Iran, Islamic Republic of |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
21 | NCT01228266 (ClinicalTrials.gov) | December 2010 | 25/10/2010 | Mesenchymal Stem Cell Transplantation in MS | Autologous Mesenchymal Stem Cell Transplantation in Multiple Sclerosis: a Randomized, Double-blind, Crossover With Placebo Phase II Study | Multiple Sclerosis | Biological: autologous mesenchymal stem cells | Albert Saiz | Instituto de Salud Carlos III | Terminated | 18 Years | 50 Years | Both | 9 | Phase 2 | Spain |
22 | NCT01364246 (ClinicalTrials.gov) | January 2010 | 31/5/2011 | Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis Optica | Phase I/II Study of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis Optica | Progressive Multiple Sclerosis;Neuromyelitis Optica. | Biological: human umbilical cord mesenchymal stem cells | Shenzhen Beike Bio-Technology Co., Ltd. | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School;The Affiliated Nanjing Brain Hospital of Nanjing University Medical School;Nanjing University Medical College Affiliated Wuxi Second Hospital;Xuzhou Medical College;The Second Hospital of Nanjing Medical University | Recruiting | 18 Years | 60 Years | Both | 20 | Phase 1;Phase 2 | China |
23 | NCT00781872 (ClinicalTrials.gov) | October 2006 | 28/10/2008 | Mesenchymal Stem Cells for the Treatment of MS | Explorative Trial to Investigate the Migration Ability of Mesenchymal Bone Marrow Stem Cells (MSC) in the Central Nervous System (CNS) Following Their Intrathecal Administration in Severe Cases of Multiple Sclerosis (MS) | Multiple Sclerosis | Biological: injection of autologous stem cells | Hadassah Medical Organization | NULL | Completed | 35 Years | 65 Years | All | 20 | Phase 1;Phase 2 | NULL |
24 | EUCTR2015-000137-78-AT (EUCTR) | 17/09/2015 | Mesenchymal stem cells therapy for patients with multiple sclerosis | Randomised, double-blind, cross-over phase II study with intravenous autologous mesenchymal stem cells vs. placebo for multiple sclerosis patients in Austria (MESEMS Austria) | multiple sclerosis;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Human autologous mesenchymal stem cells INN or Proposed INN: MSC2015 Other descriptive name: UNDIFFERENTIATED AUTOLOGOUS MESENCHYMAL STEM CELLS | SALK - Gemeinnützige Salzburger Landeskliniken Betriebsges. m.b.H., Christian-Doppler-Klinik, UK für Neurologie der PMU | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Phase 2 | Austria |